|
ADAL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.081290E-03 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
3.563500E-04 |
| Stage1-vs-Stage3 |
2.713900E-02 |
| Stage1-vs-Stage4 |
1.62616999999088E-05 |
| Stage2-vs-Stage3 |
4.69499999999901E-06 |
| Stage2-vs-Stage4 |
3.95600000535623E-08 |
| Stage3-vs-Stage4 |
6.228200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.0055736505451E-12 |
| Normal-vs-Asian |
1.62436730732907E-12 |
| Caucasian-vs-AfricanAmerican |
1.642010E-01 |
| Caucasian-vs-Asian |
1.499450E-01 |
| AfricanAmerican-vs-Asian |
7.720200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.546400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
6.96476210038099E-12 |
| Normal-vs-Age(81-100Yrs) |
2.80839999999838E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.830000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.696100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.993800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.868820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.630400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.017200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.01809704900325E-11 |
| Classical-VS-Follicular |
1.41350264826201E-11 |
| Classical-VS-Other |
7.082600E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.62447832963153E-12 |
| Tall-VS-Other |
7.344200E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.284420E-02 |
| Follicular-VS-Normal |
5.622600E-04 |
| Other-VS-Normal |
1.98490000002938E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.94900000000309E-06 |
|
|
